^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    C019199

    i
    Other names: C019199
    Associations

    News

    Trials
    Company:
    Fujian Haixi New Pharmaceutical
    Drug class:
    VEGFR-2 inhibitor, CSF-1R inhibitor, DDR1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2years
    Phase 1 study of C019199, an oral CSF-1R/DDRs/VEGFR2 multiple kinase inhibitor, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors, including tenosynovial giant cell tumor. (ASCO 2022)
    Secondary endpoints will include pharmacokinetics, objective response rate, progression-free survival, and disease control rate. Exploratory biomarker analyses include CSF-1 and VEGF.
    Clinical • P1 data • PK/PD data • PD(L)-1 Biomarker • IO biomarker
    |
    KDR (Kinase insert domain receptor) • CSF1R (Colony stimulating factor 1 receptor)
    |
    C019199